Helixyte mRNA转染试剂 货号60030-AAT Bioquest荧光染料

上海金畔生物科技有限公司代理AAT Bioquest荧光染料全线产品,欢迎访问AAT Bioquest荧光染料官网了解更多信息。

Helixyte mRNA转染试剂

Helixyte mRNA转染试剂

Helixyte mRNA转染试剂    货号60030 货号 60030 存储条件 在2-8度冷藏保存, 避免光照
规格 500 ul 价格 2340
Ex (nm) Em (nm)
分子量 溶剂 Water
产品详细介绍

简要概述

Helixyte mRNA 转染试剂是一种功能强大且用途广泛的转染试剂,它是将更多的 mRNA 引入真核细胞,或更具体地说,引入动物细胞。 它在各种贴壁和悬浮细胞系中提供高转染效率,包括难以转染的细胞。不需要核摄取,这导致比 DNA 转染更快的蛋白质表达,而没有基因组整合的风险。 Helixyte mRNA转染试剂的低毒性可提高转染细胞的生存能力。 Helixyte mRNA 转染试剂不需要特殊培养基,与大多数商业转染试剂相比更易于使用。

产品说明书

样品实验方案

简要概述

1.准备转染细胞
2.制备 Helixyte mRNA 转染试剂-RNA 混合物
3.将 Helixyte mRNA 转染试剂-RNA 混合物添加到细胞培养物中
4.过夜培养细胞
5.用合适的方法分析转染效率

 

细胞准备

1.在转染时将细胞培养至 ~ 90% 汇合。
2.转染前更换新鲜培养基。例如,6 孔板每孔更换 2 mL 培养基,10 cm 板更换 6 mL 培养基。

 

工作溶液配制

1.Helixyte mRNA 转染试剂-RNA 混合物
2.将 2.5 µg mRNA 与 200 µL 无血清培养基混合。
3.在步骤 1 中加入 7.5 µL Helixyte mRNA 转染试剂。
4.混匀并在室温下孵育 20 分钟。
注意:Helixyte mRNA 转染试剂与 mRNA 的比例需要针对不同的细胞系进行优化。 通常,Helixyte mRNA 转染试剂 (µL) 与 mRNA (µg) 的比率 =(3 至 5 µL)至 1 µg。

6孔板样品方案

组分 6孔板(每孔)
新鲜培养基 2ml
纯化的mRNA -2.5ug
无血清培养基 200ul
Helixyte mRNA 转染试剂 -7.5ul

 

操作步骤

1.转染方案

1.1将 Helixyte mRNA 转染试剂 – mRNA 混合物加入培养板并培养过夜。
注意:重组蛋白表达可以在转染后的8小时内检测到。 转染后约24小时可观察到最大表达水平。

Helixyte mRNA转染试剂    货号60030

图 1. HeLa 细胞中的转染效率比较(上图)和细胞毒性比较(下图)。 HeLa 细胞在 6 孔板中培养至~90% 汇合。 2.5 µg mRNA 分别用 Lipofactamin MessengerMAX 和 Helixyte mRNA 转染试剂转染。 转染后 18 小时,使用带有 FITC 通道的荧光显微镜(上图)拍摄图像。 Lipofactamin MessengerMAX 和 Helixyte mRNA 转染试剂的转染效率相似。用 Helixyte mRNA 转染试剂转染的细胞看起来比用 Lipofatamin MessengerMAX 转染的细胞健康得多(下图)。

 

参考文献

A Systematic Study of Unsaturation in Lipid Nanoparticles Leads to Improved mRNA Transfection In Vivo.
Authors: Lee, Sang M and Cheng, Qiang and Yu, Xueliang and Liu, Shuai and Johnson, Lindsay T and Siegwart, Daniel J
Journal: Angewandte Chemie (International ed. in English) (2021): 5848-5853

A synthetic mRNA cell reprogramming method using CYCLIN D1 promotes DNA repair generating improved genetically stable human induced pluripotent stem cells.
Authors: Alvarez-Palomo, Ana Belén and Requena-Osete, Jordi and Delgado-Morales, Raul and Moreno-Manzano, Victoria and Grau-Bove, Carme and Tejera, Agueda M and Otero, Manel Juan and Barrot, Carme and Santos-Barriopedro, Irene and Vaquero, Alejandro and Mezquita-Pla, Jovita and Moran, Sebastian and Naya, Carlos Hobeich and Garcia-Martínez, Iris and Pérez, Francisco Vidal and Blasco, María A and Esteller, Manel and Edel, Michael J
Journal: Stem cells (Dayton, Ohio) (2021)

CD40 signaling augments IL-10 expression and the tolerogenicity of IL-10-induced regulatory dendritic cells.
Authors: Dawicki, Wojciech and Huang, Hui and Ma, Yanna and Town, Jennifer and Zhang, Xiaobei and Rudulier, Chris D and Gordon, John R
Journal: PloS one (2021): e0248290

Expediting in vitro characterization of mRNA-based gene therapies via high-content fluorescent imaging.
Authors: Vigil, Toriana N and Zhang-Hulsey, Diana and Santos, Jose Luis and Patrick Hussmann, G
Journal: Analytical biochemistry (2021): 114259

LipoParticles: Lipid-Coated PLA Nanoparticles Enhanced In Vitro mRNA Transfection Compared to Liposomes.
Authors: Ayad, Camille and Libeau, Pierre and Lacroix-Gimon, Céline and Ladavière, Catherine and Verrier, Bernard
Journal: Pharmaceutics (2021)

Live-cell Imaging of Single-Cell Arrays (LISCA) – a Versatile Technique to Quantify Cellular Kinetics.
Authors: Reiser, Anita and Woschée, Daniel and Kempe, Simon Maximilian and Rädler, Joachim Oskar
Journal: Journal of visualized experiments : JoVE (2021)

Location of a single histidine within peptide carriers increases mRNA delivery.
Authors: He, Jiaxi and Xu, Songhui and Leng, Qixin and Mixson, A James
Journal: The journal of gene medicine (2021): e3295

PEGylation of poly(amine-co-ester) polyplexes for tunable gene delivery.
Authors: Grun, Molly K and Suberi, Alexandra and Shin, Kwangsoo and Lee, Teresa and Gomerdinger, Victoria and Moscato, Zoe M and Piotrowski-Daspit, Alexandra S and Saltzman, W Mark
Journal: Biomaterials (2021): 120780

Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma.
Authors: Lin, Liang and Cho, Shih-Feng and Xing, Lijie and Wen, Kenneth and Li, Yuyin and Yu, Tengteng and Hsieh, Phillip A and Chen, Hailin and Kurtoglu, Metin and Zhang, Yi and Andrew Stewart, C and Munshi, Nikhil and Anderson, Kenneth C and Tai, Yu-Tzu
Journal: Leukemia (2021): 752-763

Sustained release of PKR inhibitor C16 from mesoporous silica nanoparticles significantly enhances mRNA translation and anti-tumor vaccination.
Authors: Zhang, Wei and Liu, Yi and Min Chin, Jas and Phua, Kyle K L
Journal: European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V (2021): 179-187

说明书
Helixyte mRNA转染试剂.pdf